Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;73(6):573-81.
doi: 10.1002/pros.22597. Epub 2012 Oct 11.

CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer

Manisha Agarwal  1 , Chang He, Javed Siddiqui, John T Wei, Jill A Macoska
Affiliations

CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer

Manisha Agarwal et al. Prostate. 2013 May.

Abstract

Background: The recent recommendation of the U.S. Preventive Services Task Force against PSA-based screening for prostate cancer was based, in part, on the lack of demonstrated diagnostic utility of serum PSA values in the low, but detectable range to successfully predict prostate cancer. Though controversial, this recommendation reinforced the critical need to develop, validate, and determine the utility of other serum and/or urine transcript and protein markers as diagnostic markers for PCa. The studies described here were intended to determine whether inflammatory cytokines might augment serum PSA as a diagnostic marker for prostate cancer.

Methods: Multiplex ELISA assays were performed to quantify CCL1, CCL2, CCL5, CCL8, CCL11, CCL17, CXCL1, CXCL5, CXCL8, CXCL10, CXCL12, and IL-6 protein levels in the serum of 272 men demonstrating serum PSA values of <10 ng/ml and undergoing a 12 core diagnostic needle biopsy for detection of prostate cancer. Logistic regression was used to identify the associations between specific chemokines and prostate cancer status adjusted for prostate volume, and baseline PSA.

Results: Serum levels for CCL1 (I-309) were significantly elevated among all men with enlarged prostates (P < 0.04). Serum levels for CCL11 (Eotaxin-1) were significantly elevated among men with prostate cancer regardless of prostate size (P < 0.01). The remaining 10 cytokines examined in this study did not exhibit significant correlations with either prostate volume or cancer status.

Conclusions: Serum CCL11 values may provide a useful diagnostic tool to help distinguish between prostatic enlargement and prostate cancer among men demonstrating low, but detectable, serum PSA values.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Serum CCL11 levels increase the diagnostic utility of serum PSA and PCPTRC risk analysis to predict prostate cancer
Receiver-Operator Curves demonstrating the ability of serum PSA, PCPTRC (PCTP), and serum CCL11, alone or in combination, to predict prostate cancer on patients with serum PSA <10 ng/ml (N=272). The Area Under the Curve (AUC) for each measure is indicated in parentheses.
See this image and copyright information in PMC

References

    1. Luciani LG, De Giorgi G, Valotto C, Zanin M, Bierti S, Zattoni F. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings. Urology. 2006;67(3):555–8. - PubMed
    1. Inahara M, Suzuki H, Kojima S, Komiya A, Fukasawa S, Imamoto T, et al. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology. 2006;68(4):815–9. - PubMed
    1. Kravchick S, Peled R, Dorfman D, Agulansky L, Ben-Dor D, Cytron S. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL. Urology. 2005;66(3):542–6. - PubMed
    1. Pelzer AE, Tewari A, Bektic J, Berger AP, Frauscher F, Bartsch G, et al. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project. Urology. 2005;66(5):1029–33. - PubMed
    1. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65(3):549–53. - PubMed

Publication types